To compare the intraocular pressure (IOP)-lowering effect of 0.005% latanoprost used once every other day versus once daily in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT).
Methods:
Forty eyes of 20 patients with bilateral OHT or early POAG were enrolled in this prospective, randomized, crossover study. After a washout period of 1–4 weeks, each patient started latanoprost once daily in 1 randomly assigned eye and once every other day in the other eye. After 1 month, eyes were crossed over to the opposite dosing regimen for another month. IOP was measured at 9 am, 4 pm, and 9 pm, both at baseline and on 2 consecutive days, at the end of the first and second months. The main outcome measure was IOP reduction on the second day at the end of the first and second months.
Results:
Mean±standard deviation (SD) baseline IOPs (mmHg) in the right and left eye were 25.6±2.6 and 25.5±2.7 (P=0.8), respectively. Mean±SD diurnal IOPs decreased (mmHg) by 8.6±2.5 in the once-daily group versus 7.3±2.3 in the every-other-day group (P<0.001) at the end of the first month and 8.4±2.5 versus 7.7±2.5 at the end of the second month (both on day 2) (P=0.01).
Conclusions:
Once every-other-day administration of latanoprost significantly reduced the IOP although the IOP reduction was less pronounced 36–48 h after drug application.
Get full access to this article
View all access options for this article.
References
1.
ParrishR.K., PalmbergP., SheuW.P.XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12 week, randomized, masked-evaluator multicenter study. Am. J. Ophthalmol., 135:688–703. 2003.
2.
FaridiU.A., SalehT.A., EwingsP.et al.Comparative study of three prostaglandin analogues in the treatment of newly diagnosed cases of ocular hypertension, open-angle and normal tension glaucoma. Clin. Exp. Ophthalmol., 38:678–682. 2010.
3.
Van der ValkR., WebersC.A., SchoutenJ.S.et al.Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology., 112:1177–1185. 2005.
4.
PerryC.M., McGavinJ.K., CulyC.R., IbbotsonT.Latanoprost: an update of its use in glaucoma and ocular hypertension. Drugs Aging., 20:597–630. 2003.
5.
WeinrebR.N., LindseyJ.D., LuoX.X., WangT.H.Extracellular matrix of the human ciliary muscle. J. Glaucoma., 3:70–78. 1994.
6.
OcklindA.Effect of latanoprost on the extracellular matrix of the ciliary muscle: a study on cultured cells and tissue sections. Exp. Eye Res., 67:179–191. 1998.
7.
SagaraT., GatonD., LindseyJ.D.et al.Topical prostaglandin F2α treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch. Ophthalmol., 117:794–801. 1999.
8.
LindseyJ.D., KashiwagiK., BoyleD.et al.Prostaglandins increase proMMP-1 and proMMP-3 secretion by human ciliary smooth muscle cells. Curr. Eye Res., 15:869–875. 1996.
9.
SchumerR.A., CamrasC.B., MandahlA.K.Putative side effects of prostaglandin analogs. Surv. Ophthalmol., 47,Suppl 1:S219. 2002.
10.
UusitaloH., PillunatL.E., RopoA.Phase III study investigators. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study. Acta Ophthalmol., 88:12–19. 2010.
11.
LarssonL.I.Intraocular pressure over 24 hours after single dose administration of latanoprost 0.005% in healthy volunteers. Acta Ophthalmol. Scand., 79:567–571. 2001.
12.
LarssonL.I., MishimaH.K., TakamatsuM., OrzalesiN., RossettiL.The effect of Latanoprost on circadian intraocular pressure. Surv. Ophthalmol., 47,Suppl 1:S90–S96. 2002.
13.
StewartW.C., HolmesK.T., JohnsonM.A.Washout periods for brimonidine 0.2% and latanoprost 0.005%Am. J. Ophthalmol., 131:798–799. 2001.
14.
DarhadU., NakamuraM., FujiokaM.et al.Intraocular pressure lowering effect of once daily versus once weekly instillation in the same normal individuals. Kobe J. Med. Sci., 53:297–304. 2008.
15.
KurtzS., ShemeshG.The efficacy and safety of once-daily versus once-weekly latanoprost treatment for increased intraocular pressure. J. Ocul. Pharmacol. Ther., 20:321–327. 2004.
16.
LeskeM.C., HeijlA., HusseinM.et al.Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment. Arch. Ophthalmol., 121:48–56. 2003.
17.
LeskeM.C., HeijlA., HymanL.et al.EMGT Group. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology., 114:1965–1972. 2007.
18.
SchumanJ.S.Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Surv Ophthalmol., 41,suppl:S27–S37. 1996.
19.
StrahlmanE., TippingR., VogelR.International Dorzolamide Study Group. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. Arch. Ophthalmol., 113:1009–1016. 1995.
20.
StewartR.H., KimbroughR.L., WardR.L.Betaxolol vs timolol. A six-month double-blind comparison. Arch. Ophthalmol., 104:46–48. 1986.
21.
BoyleJ.E., GhoshK., GieserD.K., AdamsonsI.A.Dorzolamide Timolol Study Group. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Ophthalmology, 105:1945–1951. 1998.
22.
SallK.Brinzolamide Primary Therapy Study Group. The efficacy and safety of brinzolamide 1% ophthalmic suspension (Azopt) as a primary therapy in patients with open-angle glaucoma or ocular hypertension. Surv. Ophthalmol., 44,suppl:S155–162. 2000.
23.
KampikA., Arias-PuenteA., O'BrartD.P., VuoriM.L.European Latanoprost Study Group. Intraocular pressure-lowering effects of latanoprost and brimonidine therapy in patients with open-angle glaucoma or ocular hypertension: a randomized observer-masked multicenter study. J. Glaucoma., 11:90–96. 2002.
24.
BahlerC.K., HowellK.G., HannC.R., FautschM.P., JohnsonD.H.Prostaglandins increase trabecular meshwork outflow facility in cultured human anterior segments. Am. J. Ophthalmol., 145:114–119. 2008.
25.
JohnstoneM., JamilA., MartinE. Latanoprost instillation results in a rapid, directly measurable increase in conventional aqueous outflow in normal subjects. Presented at the American Glaucoma Society 18th Annual Meeting, Washington, DC, 2008.
26.
DjafariF., LeskM.R., HarasymowyczP.J., DesjardinsD., LachaineJ.Determinants of adherence to glaucoma medical therapy in a long-term patient population. J. Glaucoma., 18:238–243. 2009.
27.
RobinA.L., NovackG.D., CovertD.W., CrockettR.S., MarcicT.S.Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am. J. Ophthalmol., 144:533–540. 2007.
28.
OkekeC.O., QuigleyH.A., JampelH.D.Adherence with topical glaucoma medication monitored electronically the Travatan Dosing Aid study. Ophthalmology., 116:191–199. 2009.
29.
FriedmanD.S., OkekeC.O., JampelH.D.Risk factors for poor adherence to eye drops in electronically monitored patients with glaucoma. Ophthalmology., 116:1097–1105. 2009.
30.
HigginbothamE.J., OlanderK.W., KimE.E. United States Fixed-Combination Study Group. Fixed combination of latanoprost and timolol vs. individual components for primary open-angle glaucoma or ocular hypertension. Arch. Ophthalmol., 128:165–172. 2010.
31.
FeldmanR.M.Conjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertension. J. Ocul. Pharmacol. Ther., 19:23–35. 2003.
